bioMerieux (OTCMKTS:BMXMF) Shares Gap Up – What’s Next?

bioMerieux (OTCMKTS:BMXMF) shares gapped up before the market opened on Friday . The stock had previously closed at $77.38, but opened at $82.91. bioMerieux shares last traded at $82.75, with a volume of 105 shares trading hands.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. BNP Paribas Exane cut bioMerieux to a “neutral” rating in a report on Wednesday, January 28th. Zacks Research raised bioMerieux to a “hold” rating in a report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft cut bioMerieux from a “buy” rating to a “hold” rating in a report on Friday, April 24th. Four analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has an average rating of “Hold”.

bioMerieux Trading Up 0.4%

The company has a fifty day moving average of $107.39 and a 200 day moving average of $118.16. The company has a current ratio of 2.39, a quick ratio of 1.48 and a debt-to-equity ratio of 0.08.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.